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SIGNIFICANCE STATEMENT 37
Economic growth, an increasingly sedentary lifestyle and a nutritional transition to processed foods 38 and high calorie diets have led to a significant increase in obesity prevalence. Several chronic diseases 39 have been associated with obesity, including dementia. Obesity-induced, peripheral inflammation has 40 been proposed as a possible trigger of pathological changes in the brain that lead to cognitive 41 dysfunction and predisposition to dementia. Here we show that genetic deletion of the complement 42 component C1QA prevents cerebrovascular damage, neuroinflammation and white matter degradation 43 in a mouse model of western diet-induced obesity, demonstrating that inflammatory responses play a 44 significant role in obesity-induced brain pathology. The complement pathway is an attractive 45 therapeutic target to prevent cognitive decline and reduction of dementia risk caused by obesity. 46
INTRODUCTION 47
Over the last 30 years obesity prevalence has significantly increased in many countries to the point that 48 one third of the world population is overweight or obese (Hruby and Hu, 2015) . In fact, it is projected 49 that in the USA over 85% of adults will be overweight or obese by 2030 (Wang et al., 2008; Hruby and 50 Hu, 2015) . Obesity has been defined as an excess of body weight for height (body mass index >29). 51
However, because of its metabolic alterations and increased risk for the development of chronic 52 diseases, obesity is now considered an energy metabolism disorder (Hruby and Hu, 2015) . Moreover, 53 obesity has also been associated with the development of mental disorders, cognitive dysfunction and how obesity promotes pathological changes in the brain that are not necessarily associated to chronic 56 conditions such as metabolic syndrome and Type 2 diabetes. Nonetheless, obesity-induced 57 inflammation has been identified as a possible trigger of pathological changes in the brain that lead to 58 cognitive dysfunction and predisposition to neurodegenerative diseases like multiple sclerosis and 59
Alzheimer's disease (AD) (Miller and Spencer, 2014) . 60 61 Previous studies in our laboratory have shown that western diet (WD)-induced obesity amplifies 62 neuroinflammation in the cortex and hippocampus of aged mice and in a mouse model of AD (Graham 63 et al., 2016; Graham et al., 2019) . More recently, we found significant infiltration of peripheral 64 myeloid cells and neutrophils in the brain of diet-induced obese mice, particularly in the cortex, the 65 hippocampus and the corpus callosum (Yang, 2019) . These strong neuroinflammatory responses are 66 accompanied by behavioral deficits, neurovascular decline and increased degradation of myelin by 67 resident microglia or peripherally-derived myeloid cells, despite the increased expression of myelin 68 proteins by oligodendrocytes (Graham et al., 2016; Graham et al., 2019) . Importantly, white matter 69 integrity throughout the corpus callosum and frontal white matter is reduced in cognitively normal 70 older adults, patients with mild cognitive impairment (MCI) and AD patients who are obese (Graham 71 et al., 2019) , suggesting that white matter damage is a pathological hallmark of obesity. 72
73
It can be presumed that the chronic low-grade inflammatory state in obesity influences the 74 neurovascular decline and the activation of microglia observed in the brain leading to subsequent 75 phagocytosis of myelin, but this has not been critically tested. Furthermore, in vitro studies have shown 76 that myelin opsonization with complement components and the presence of the complement receptor 77 CR3 by microglia are required for maximal phagocytosis of myelin, suggesting an important role of 78 the complement pathway in myelin phagocytosis (DeJong and Smith, 1997). It has been shown that in 79 multiple sclerosis lesions complement components colocalize with areas of active myelin degradation 80 along with the increased density of microglia/macrophages expressing complement receptors (Barnett 81 et al., 2009; Grajchen et al., 2018; Loveless et al., 2018) . Although, it is known that several 82 components of the classical complement pathway are produced by adipose and peripheral immune 83 cells in obese mice (Zhang et al., 2007) , evidence of activation of the complement pathway in the brain 84 during obesity is lacking. Here, we hypothesized that myelin phagocytosis by microglia (or 85 peripherally-derived myeloid cells) in WD-induced obese mice was mediated by the activation of the 86 classical complement pathway. We found that genetic deletion of C1qa did not change the body 87 composition or common blood-based markers of metabolic syndrome in the western diet-induced 88 obese mice. However, C1QA deficiency did significantly lessen cerebrovascular damage and the 89 activation and phagocytic activity of microglia in the cortex, hippocampus and corpus callosum 90 preventing the degradation of myelin. All methods are in accordance with The Jackson Laboratory Institutional Animal Care and Use 95 Committee (IACUC) approved protocols. C57BL/6J (B6) mice (JAX stock # 000664), 96 B6.C1qa tm1a(EUCOMM)Wtsi /J, and B6.C3 tm1Crr /J (Jax stock #003641) mice were used in this study and maintained in 97 the Howell Lab colony. B6.C1qa tm1a(EUCOMM)Wtsi /J mice were created by backcrossing B6N.C1qa tm1a(EUCOMM)Wtsi /J 98 mice at least 10 generations to C57BL/6J. Males were initially used exclusively in this study to avoid 99 effects of the estrus cycle, but a second cohort of male and female mice were used to determine 100 possible sex differences in response to both diet and complement deficiency. All mice were maintained 101 on a 12/12 hours (hrs) light/dark cycle. Cohorts were maintained from wean on standard LabDiet® 102 5K52 (referred to as "Control diet" or "CD"). Half of the cohorts were switched to TestDiet® 5W80 103 (referred to as "Western diet" or "WD") (Graham et al., 2016) . 104 105
Metabolic profiling 106
Glucose and insulin tolerance test: Glucose and insulin tolerance tests were performed in 12 mos mice, 107 following 10 mos on the WD. After fasting for 5 hours, glucose tolerance test (GTT) was performed 108 (Agri Laboratories, LTD). For the insulin tolerance test (ITT), mice received a single intraperitoneal 109 injection of a diluted insulin solution (males 0.75 IU/kg and females 0.50 IU/kg; prepared in sterile 110 saline) (Humulin R U-100, Eli Lilly). Glucose was determined using a handheld glucometer (Bayer 111 Contour Next). 112 NMR Body Composition: Body composition was determined in the Echo MRI 3-in-1, time domain 113 nuclear magnetic resonance (TD-NMR) system (Houston, TX). Body weight was measured on a 7 standard laboratory balance before mice were placed in to a clear, cylindrical holder. The tube was 115 gently inserted in to the boor for an approximately two-minute measurement. Adiposity (% body fat) 116 was calculated as ((fat mass/total body weight) x 100). 117
Plasma lipid measurements: Blood was collected in K2 EDTA (1.0mg) microtainer tubes (BD) at 118 harvest (non-fasted) and kept at room temperature for at least 30 minutes to prevent clotting and then 119 centrifuged at 22°C for 15 minutes at 5000rpm. Plasma was carefully collected and aliquoted. Plasma 120 was characterized on the Beckman Coulter AU680 chemistry analyzer. 121 122
Behavioral battery 123
All the tasks performed by The Jackson Laboratory's Mouse NeuroBehavioral Facility (MNBF) were 124 previously validated using control B6 mice. The spontaneous alternation task, a measure of working 125 memory, was conducted as previously described (Sukoff Rizzo et al., 2018) . Briefly, a clear Plexiglas 126 Y-maze was used under adjusted, ambient lighting (~ 50 lux). Subject mice were acclimated to the 127 testing room for 1hr prior to testing. Tested mice were then placed midway of the start arm (A), facing 128 the center of the Y for an 8-minute test period, and the sequence of entries into each arm are recorded 129 via a ceiling mounted camera integrated with behavioral tracking software (Noldus Ethovision). The 130 percentage of spontaneous alternation was calculated as the number of triads (entries into each of the 3 131 different arms of the maze in a sequence of 3 without returning to a previously visited arm) relative to 132 the number of alteration opportunities. 133
For assessment of open field activity, Open Field Arenas (40 cm × 40 cm × 40 cm; Omnitech 134
Electronics, Columbus, OH) were used. A light fixture mounted ∼50 cm above the center of each 135 arena provided a consistent illumination of ∼400-500 lux in the center of the field. Before the test, 136 mice were acclimated to an anteroom outside the testing room for a minimum of 1 hour. Subsequently, 137 the tested mice were placed individually into the center of the arena where the infrared beams recorded 138 distance traveled (cm), vertical activity, and perimeter/center time. 139
For grip strength, subjects were weighed and acclimated for at least 1hr prior to the test. All the grip 140 strength tests were assessed using the Bioseb grip strength meter equipped with a grid suited for mice. 141
For forepaw and four paw grip strength testing, mice were lowered towards the grid by their tails to 142 allow for visual placing and for the mouse to grip the grid with their paws. Subjects were firmly pulled 143 horizontally away from the grid (parallel to the floor) for 6 consecutive trials with a brief (<30 sec) rest 144 period on the bench between trials. Trials 1-3 tested only the forepaw grip; while the following trials 4-145 6 included all four paws. The average of the 3 forepaw trials and the average of the 3 four paw trials 146
were analyzed with and without normalization for body weight. 147 148
Mouse perfusion and tissue preparation 149
Tissue was collected at 3.5 mos, 12 mos, and 20 mos (aged C3 mice). Mice were anesthetized with a 150 lethal dose of ketamine/xylazine, transcardially perfused with 1X phosphate buffered saline (PBS) and 151 brains carefully dissected and hemisected in the midsagittal plane. One half was snap-frozen, the other 152 half immersion fixed in 4% paraformaldehyde (PFA) for two nights at 4ºC. After fixation, half brains 153 were rinsed in 1 x PBS, immersed in 30% sucrose (in 1 x PBS) overnight at 4ºC before being frozen in 154
Optimal Cutting Temperature (OCT) compound. Tissue was cryosectioned at 25µm on to glass slides 155 for RNA in situ hybridization and immunofluorescence. 
Imaging and quantification 184
Imaging: For each mouse, four images per brain region (parietal cortex, corpus callosum and CA1 185 region of the hippocampus) were generated. Quantifications were performed per image -therefore 186
where images contained multiple brain regions (e.g. parietal cortex, corpus callosum and CA1 region 187 of the hippocampus) these were batched together (see Experimental design and statistical analysis for 188 more details). For quantifying cell number or area, images were captured on a Zeiss AxioImager 189 microscope. For each antibody, all images were captured using identical parameters for accurate 190 quantification. Where possible, fluorescent intensity was standardized to samples from CD-fed mice. 191
However, given the striking difference in intensity between CD-fed and WD-fed mice for MPB, 192
images were standardized to WD-fed mice. 
RESULTS 227
Transcriptional profiling demonstrated that WD-induced obese male mice have an increased 228 expression of complement components, including the central components C1qa, C1qb, C1qc and C3, 229
in the brain when compared to non-obese mice fed a control diet (CD) (Fig. 1A, (Graham et al.,  230 2019)). To determine the location and extent of complement deposition in the brain of obese mice, 231 male mice were fed either a WD or CD from 2 months of age (mos) for 10 months. RNA in situ 232 hybridization in 12 mos brains showed a significant increase in the numbers of C1qa+ expressing cells 233 in the cortex and hippocampus from WD-fed compared to CD-fed mice ( Fig. 1B-C) . Also, the 234 intensity and size of staining for each C1qa+ cell appeared greater in WD-fed compared to CD-fed 235 mice, features previously suggested to represent activated myeloid cells (Davis et al., 2017) . C1Q and 236 C3 immunostaining appeared greater in the corpus callosum in WD-fed compared to CD-fed mice 237 (Fig. 2) . Little to no C1Q or C3 immunostaining was observed in the corpus callosum of young mice 238 or in brains from mice deficient in C1qa and C3 (Fig. S1) . The increase in complement components in 239 WD-fed compared to CD-fed mice appeared due to changes in microglia as C1Q and C3 240 immunoreactivity co-localized with IBA1 -a marker of microglia. 241
242
To elucidate the role of complement activation in brains of obese mice, B6.C1qa -/-(C1qa KO) mice 243 were generated (see methods, Fig. S2A ). RNA in situ hybridization with C1qa riboprobes confirmed 244 the complete absence of C1qa expression in the brain of B6.C1qa -/-mice ( Fig. S2B, C) . Cohorts of 10-245 12 male and female C1qa KO and B6 (WT) control mice were established. At 2 mos, mice were fed 246 either a WD or a CD. At 12 mos, mice were assessed for characteristics of metabolic syndrome that 247 included weight, glucose and insulin tolerance. WD-fed C1qa KO male and female mice both gained 248 weight similarly to their WD-fed WT littermate controls (Fig. 3A, C) . Consistent with higher total 249 weight, the percentage of adiposity was greater in males and females from both WD-fed mouse strains 250 when compared to CD-fed mice (Fig. 3B, D) . Lipid profiling of plasma from WD-fed and CD-fed 251 mice showed that total cholesterol levels in males and females were increased in both C1qa KO and 252 WT mice when compared to CD-fed mice (Fig. 3E, G) . Triglyceride levels were decreased in C1qa 253 KO males and unchanged in females from WT and C1QA deficient mice (Fig. 3F, H) . The levels of 254 LDL were only increased in males by the WD in both mouse strains (Fig. 3I, K) , while HDL levels 255 were increased in both females and males from WD-fed mice (Fig. 3J, L) . Changes in the level of fatty 256 acids were not found in any of the experimental groups (Fig. 3M, N) . Obesity is a high risk for insulin 257 resistance, therefore glucodynamic responses were evaluated in WD-fed and CD-fed WT and C1QA 258 deficient mice. While no changes in blood glucose levels were found in the basal, non-fasting state 259 ( Fig. 4A, C) , only WD-fed WT males presented a moderate impaired glucose tolerance, that was 260 prevented by the deficiency of C1QA in the WD-fed C1qa KO males (Fig. 4B, D) . Finally, no 261 differences in insulin levels were observed ( Fig. 4E-H) . Collectively these data show WD-fed C1qa 262 KO and WT mice were obese but not insulin resistant or diabetic. 263
264
Cognitive health was tested in in all mice at 12 mos using a previously validated spontaneous 265 alternation Y-maze task, a measure of working memory (Graham et al., 2019) . Male and female CD-266 fed mice were able to perform the task. In contrast, WD-fed male WT mice showed a significant 267 impairment in their ability to alternate between the arms of the Y-maze indicative of a deficit in 268 working memory ( Fig. 5A-D) . In contrast, male and female C1qa KO mice either fed the WD or the 269 CD were able to perform the task (Fig. 5A-D) . No differences in locomotor activity levels (Fig. 5E, G ) 270 and grip strength (Fig. 5F, H) were found between the experimental groups. These data suggest that 271 although C1QA deficiency did not alter obesity it did prevent deficits in working memory observed in 272 WD-fed male mice. with increased expression of C1qa in myeloid cells (Soto et al., 2015) . To determine the potential for 281 complement inhibition to prevent cerebrovascular damage in obesity, we first assessed pericytes 282 number using platelet derived growth factor receptor beta (PDGFRb) immunoreactivity. The number 283 of PDGFRb + cells was significantly reduced in WD-fed WT obese mice compared to CD-fed WT mice 284 ( Fig. 6A-B) . In contrast, there was no significant difference in the numbers of PDGFRb + cells in C1qa 285 KO mice fed either the WD or CD. We next assessed laminin, a major component of the basement 286 membrane. While there was a significant decrease in the density of laminin + capillaries in WD-fed WT 287 obese mice when compared to CD-fed mice, no significant difference was found in WD-fed C1qa KO 288 obese mice when compared to mice fed the CD (Fig. 6A, C) . These results suggest C1Q plays a role in 289 obesity-induced cerebrovascular damage. 290 291 High fat diets, westernized diets and obesity have been shown to induce systemic inflammation, 292
including proinflammatory responses in peripheral tissues and can lead to neuroinflammation and 293 cognitive decline (Ownby, 2010) . In this study (Figs. 1-2) and our previous studies (Soto et al., 2015; 294 protein in the brains of WD-fed obese mice. As reported recently by our group, increased phagocytosis 296 of myelin by microglia is observed in WD-fed obese mice (Graham et al., 2019) . Therefore, to 297 determine if C1QA deficiency prevents obesity-induced phagocytic activity of microglia and myelin 298 degradation, brain sections that contained a portion of the CA1 region of the hippocampus, corpus 299 callosum and cortex from 12 mos WD-fed and CD-fed C1qa KO and WT mice were immunostained 300 for IBA1 (myeloid cells marker), CD68 (lysosomes/phagosomes) and MBP (myelin basic protein). 301
Images were processed and analyzed using IMARIS (with brain regions batched together, see 302
Methods). There were significantly greater IBA1 + surfaces in the WD-fed WT compared to CD-fed WT 303 mice ( Fig. 7A-D, E ). There were also significantly greater CD68 + surfaces in WD-fed WT compared to 304 CD-fed WT mice ( Fig. 7A-D, F) , indicative of increased phagocytic activity. Deficiency of C1QA 305 prevented the increase in both IBA1 + and CD68 + surfaces in WD-fed C1qa KO mice (Fig. 7E, F) . 306 307 Phagocytosis of myelin by activated microglia is increased in the presence of complement proteins 308 (DeJong and Smith, 1997). Therefore, myelin positive regions in a portion of the CA1 region of the 309 hippocampus, the corpus callosum and the parietal cortex were assessed using MBP, a major 310 constituent of myelin. Images were again processed and analyzed using IMARIS (see Methods). As 311 expected based on our previous study (Graham et al., 2019) , MBP + surfaces in brain sections from 312 WD-fed WT mice were significantly decreased when compared to CD-fed WT mice, particularly in the 313 corpus callosum (Fig. 8A, B, D) . However, no changes in MBP levels were found in brain sections of 314 WD-fed C1qa KO compared to CD-fed WT and C1qa KO mice, indicating that deficiency of C1QA 315 prevented the obesity-induced degradation of myelin. Next, the interactions of IBA1 + cells with MBP 316 immunostained myelin were assessed. MBP:IBA1 (myelin-myeloid cells) interactions were 317 significantly increased in WD-fed WT mice compared to CD-fed WT mice (Fig. 8A, B, E) . 318
Colocalization of MBP + surfaces with both CD68 + and IBA1 + surfaces were commonly observed in 319 WD-fed WT mice but were not observed in WD-fed C1qa KO mice (Fig. 8C) . These findings suggest 320 C1QA deficiency prevented the phagocytosis of myelin by microglia. 321
DISCUSSION 322
The increase in many diet-and obesity-related diseases in western societies, including cardiovascular 323 disease, Type 2 diabetes and dementias have been linked to lifestyle changes. However, little is known 324 about how these changes contribute to long term brain health and increase risk for age-related Activation of the complement cascade occurs in the aging brain and in neurodegenerative diseases 336 (reviewed in (Hammond et al., 2019) ). This is the first study to support a damaging role for C1QA in 337 obesity-induced cerebrovascular damage and white matter loss. However, the role of the complement 338 cascade in aging and neurodegenerative diseases has been more widely studied. Inhibition of C1QA 339 prevented synapse loss in aging mice and in mouse models of AD, Parkinson's disease, and glaucoma 340 (Hammond et al., 2019) . However, although inhibition of C3 appeared protective to the aging brain, 341 deficiency of C3 exacerbated some phenotypes in mouse models of AD and glaucoma (Hammond et 342 al., 2019) . In our study, to assess the role of C1QA in western diet-induced obesity, we chose to focus 343 on cerebrovascular and white matter structures as well as microglia activity based on findings from 344 two previous studies (Graham et al., 2016; Graham et al., 2019) . In the first study, in response to a 345 WD, neuroinflammation was identified as a major consequence of chronic consumption of a WD. A 346 small but significant loss of neurons in the cortex but not the hippocampus was identified (Graham et 347 al., 2016) . In the second study, transcriptional profiling supported increased neuroinflammation, as 348 well as cerebrovascular and white matter changes in response to a WD (Graham et al., 2019) . In this 349 study, C1QA deficiency prevented pericyte loss and the reduction in laminin density observed in 350 vessels is significantly reduced in aged mice and correlates with an increase in C1qa-expressing 365 myeloid cells (Soto et al., 2015) . Age-dependent cerebrovascular decline is exacerbated by obesity 366 (Tucsek et al., 2014; Graham et al., 2019) . As with aging, cerebrovascular decline correlates with 367 increased expression of C1qa in myeloid cells (Soto et al., 2015) . C3 deposition has been reported on 368 cerebral vessels of AD patients, suggesting a possible role of complement in cerebrovascular decline 369 (Shi et al., 2019) . Furthermore, complement synthesis is increased in activated microglia preceding 370 blood brain barrier dysfunction in an inducible rat model of neurotoxicity, suggesting complement 371 proteins can directly damage the cerebrovasculature (Lynch et al., 2004) . In fact, it is thought that the 372 cerebrovasculature is particularly susceptible to complement components as it can be exposed to these 373 proteins that are produced in the brain and/or circulating in the blood. 
